Skip to main content
SpringerLink
Log in

Surufatinib: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Surufatinib (Sulanda®), an oral angio-immuno kinase inhibitor that selectively targets VEGFR 1, 2, and 3, FGFR1 and CSF-1R, is being developed by HUTCHMED for the treatment of solid tumours, including neuroendocrine tumours (NETs). On 30 December 2020, surufatinib received its first approval in China for the treatment of late-stage, well-differentiated, extrapancreatic NET. Surufatinib is in preregistration in China for pancreatic NET and in the USA for pancreatic and extrapancreatic NET; phase II development is underway for other solid tumours, including thyroid cancer, biliary tract carcinoma and soft tissue sarcoma. This article summarizes the milestones in the development of surufatinib leading to this first approval for extrapancreatic NET.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Xu JM, Wang Y, Chen YL, et al. Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study. Oncotarget. 2017;8(26):42076–86.

    Article  Google Scholar 

  2. HUTCHMED. Our pipeline. 2020. https://www.hutch-med.com. Accessed 4 Feb 2021.

  3. Lyons YA, Pradeep S, Wu SY, et al. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017;8(57):96496–505.

    Article  Google Scholar 

  4. Katoh M. FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (review). Int J Mol Med. 2016;38(1):3–15.

    Article  CAS  Google Scholar 

  5. HUTCHMED. Chi-Med announces the NMPA approval of surufatinib (Sulanda® in china) for non-pancreatic neuroendocrine tumors [media release]. 2020. https://www.hutch-med.com. Accessed 30 Dec 2020.

  6. HUTCHMED. Surufatinib (Sulanda): Chinese prescribing information. 2020.

  7. HUTCHMED. Chi-Med announces second NDA acceptance in China for surufatinib in pancreatic neuroendocrine tumors [media release]. 2020. https://www.hutch-med.com. Accessed 17 Sep 2020.

  8. HUTCHMED. Chi-Med initiates rolling submission of NDA to U.S. FDA for surufatinib for the treatment of advanced neuroendocrine tumors [media release]. 2020. https://www.hutch-med.com. Accessed 28 Dec 2020.

  9. HUTCHMED. Chi-med plans to submit marketing authorization application for surufatinib following scientific advice from EMA's CHMP [media release]. 2020. https://www.hutch-med.com. Accessed 10 Aug 2020.

  10. HUTCHMED. Chi-Med announces surufatinib granted U.S. FDA fast track designations for the treatment of both pancreatic and non-pancreatic neuroendocrine tumors [media release]. 2020. https://www.hutch-med.com. Accessed 17 Apr 2020.

  11. HUTCHMED. Chi-Med announces surufatinib granted FDA orphan drug designation for pancreatic neuroendocrine tumors [media release]. 2019. https://www.hutch-med.com. Accessed 25 Nov 2019.

  12. HUTCHMED, BeiGene. Chi-Med and BeiGene enter into clinical collaboration to evaluate combinations of surufatinib and fruquintinib with tislelizumab [media release]. 2020. https://www.hutch-med.com. Accessed 26 May 2020.

  13. Innovent Biologics. Innovent and Chi-Med expand global collaboration to evaluate the combination of sintilimab and surufatinib in solid tumors [media release]. 2019. https://www.hutch-med.com. Accessed 10 Oct 2019.

  14. HUTCHMED. Chi-Med enters into multiple collaborations to evaluate combinations of surufatinib and fruquintinib with PD-1 checkpoint inhibitors [media release]. 2018. https://www.hutch-med.com. Accessed 29 Nov 2018.

  15. Zhou J, Ni J, Cheng M, et al. Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF1R kinases [abstract no. 4187]. In: Proceedings of the American Association for Cancer Research Annual Meeting. 2017.

  16. Cheng M, Fan S, Tang R, et al. Evaluation of surufatinib, an orally available VEGFR, FGFR1 and CSF-1R inhibitor, in combination with immune checkpoint blockade or chemotherapy in preclinical tumor models [abstract no. 100]. Eur J Cancer. 2020;138(Suppl 2):S25.

    Article  Google Scholar 

  17. Xu J, Li J, Bai C, et al. Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, single-arm, open-label, phase Ib/II trial. Clin Cancer Res. 2019;25(12):3486–94.

    CAS  PubMed  Google Scholar 

  18. Chen J, Ji Q, Bai C, et al. Surufatinib in Chinese patients with locally advanced or metastatic differentiated thyroid cancer and medullary thyroid cancer: a multicenter, open-label, phase II trial. Thyroid. 2020;30(9):1245–53.

    Article  CAS  Google Scholar 

  19. Li K, Ma S, Miao L, et al. Absorption, metabolism and excretion of surufatinib in rats and humans. Curr Drug Metab. 2020;21(5):357–67.

    Article  CAS  Google Scholar 

  20. Qian H, Wu X, Chen Q, et al. Effects of food on the pharmacokinetic properties of surufatinib: a phase I single-dose, randomized, open-label crossover study in healthy subjects. Clin Ther. 2020;42(9):1778–86.

    Article  CAS  Google Scholar 

  21. Dasari A, Paulson AS, Hamilton E, et al. Comparison of pharmacokinetic profiles and safety of surufatinib in patients from China and the United States [abstract no. CT115]. In: American Association for Cancer Research Annual Meeting. 2020.

  22. Xu J, Shen L, Zhou Z, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(11):1500–12.

    Article  CAS  Google Scholar 

  23. Zhou Z, Xu J, Shen L, et al. Subgroup analysis by Ki-67 and primary tumour origins of the randomized, placebo-controlled phase III study of surufatinib in advanced well-differentiated extrapancreatic neuroendocrine tumours (SANET-ep) [abstract no. 1165P]. Ann Oncol. 2020;31(S4):S775.

    Article  Google Scholar 

  24. Xu J, Shen L, Bai C, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(11):1489–99.

    Article  CAS  Google Scholar 

  25. Dasari A, Li D, Sung MW, et al. Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs) [abstract no. 4610]. J Clin Oncol. 2020;38(Suppl 15):4610.

    Article  Google Scholar 

  26. Lu M, Cao Y, Gong J, et al. A phase I trial of surufatinib plus toripalimab in patients with advanced solid tumor [abstract no. CT142 plus presentation]. In: American Association for Cancer Research Annual Meeting. 2020.

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Yahiya Y. Syed

Authors
  1. Yahiya Y. Syed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yahiya Y. Syed.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahiya Y. Syed is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Syed, Y.Y. Surufatinib: First Approval. Drugs 81, 727–732 (2021). https://doi.org/10.1007/s40265-021-01489-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-021-01489-y

Search

Navigation